T1	Participants 140 202	patients with progressive castrate metastatic prostate cancer.
T2	Participants 348 429	chemotherapy-naive patients with progressive castrate metastatic prostate cancer.
T3	Participants 633 720	Between December 2001 and October 2003, 92 patients were enrolled and randomly assigned
T4	Participants 724 812	treatment with ixabepilone alone (45 patients) or in combination with EMP (47 patients).
T5	Participants 1835 1885	patients with castrate metastatic prostate cancer.
